Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v253-v254 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v254 |
|---|---|
| container_issue | |
| container_start_page | v253 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Hendifar, A. Bullock, A. Seery, T. Zheng, L. Sigal, D. Ritch, P.S. Braiteh, F.S. Zalupski, M. Bahary, N. Harris, W. Pu, J. Lian, F. Zhu, J. Wu, W. Chondros, D. Jiang, P. Hingorani, S.R. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx369.126 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx369_126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420380157</els_id><sourcerecordid>S0923753420380157</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1856-619b027175963c67145b22ae0a0ec74120c7fad092164b940df4c5f4791aedff3</originalsourceid><addsrcrecordid>eNp9kc1u2zAQhIWgAeImfYDe9mgDVUxSf2F7EtLULmAgRpGehRW5qtlKpEBSRtyX7atUhnvuaQeLncVgviR5z9k9ZzJbo7XOqvWgX7NS3nNRXiULXpQyfWA5f5MsmBRZWhVZfpO8DeEnY6yUQi6SPy_T4DwcTthP3lm0sNzWKzABEKw7Ug-tcQP6X-Q_wjcKUx8DuA7igcCj1W4wv0nDeMBAIGBb755BMAEhTvp0Ptw_bfZbwWDspwAW23RE1ZuIr9Svf9CgZtkaS7Dc15sVHAPUGzAWRk9H46bQn2Cy0RNG0h9goIghYjQKRrTqvJ6lnlTEHlCTdQq9MnZODMth_7le3SXXHfaB3v2bt8n3L08vj9t097z5-ljvUsUfijItuWyZqHhVyDJTZcXzohUCiSEjVeVcMFV1qOcWeZm3Mme6y1XR5ZXkSLrrstuEX_4q70Lw1DWjN3Nvp4az5kyouRBqLoSamdDs-XTx0BzsaMg3QRmyirTxpGKjnfmP-y8EMJ06</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hendifar, A. ; Bullock, A. ; Seery, T. ; Zheng, L. ; Sigal, D. ; Ritch, P.S. ; Braiteh, F.S. ; Zalupski, M. ; Bahary, N. ; Harris, W. ; Pu, J. ; Lian, F. ; Zhu, J. ; Wu, W. ; Chondros, D. ; Jiang, P. ; Hingorani, S.R.</creator><creatorcontrib>Hendifar, A. ; Bullock, A. ; Seery, T. ; Zheng, L. ; Sigal, D. ; Ritch, P.S. ; Braiteh, F.S. ; Zalupski, M. ; Bahary, N. ; Harris, W. ; Pu, J. ; Lian, F. ; Zhu, J. ; Wu, W. ; Chondros, D. ; Jiang, P. ; Hingorani, S.R.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx369.126</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v253-v254</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1856-619b027175963c67145b22ae0a0ec74120c7fad092164b940df4c5f4791aedff3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Hendifar, A.</creatorcontrib><creatorcontrib>Bullock, A.</creatorcontrib><creatorcontrib>Seery, T.</creatorcontrib><creatorcontrib>Zheng, L.</creatorcontrib><creatorcontrib>Sigal, D.</creatorcontrib><creatorcontrib>Ritch, P.S.</creatorcontrib><creatorcontrib>Braiteh, F.S.</creatorcontrib><creatorcontrib>Zalupski, M.</creatorcontrib><creatorcontrib>Bahary, N.</creatorcontrib><creatorcontrib>Harris, W.</creatorcontrib><creatorcontrib>Pu, J.</creatorcontrib><creatorcontrib>Lian, F.</creatorcontrib><creatorcontrib>Zhu, J.</creatorcontrib><creatorcontrib>Wu, W.</creatorcontrib><creatorcontrib>Chondros, D.</creatorcontrib><creatorcontrib>Jiang, P.</creatorcontrib><creatorcontrib>Hingorani, S.R.</creatorcontrib><title>Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u2zAQhIWgAeImfYDe9mgDVUxSf2F7EtLULmAgRpGehRW5qtlKpEBSRtyX7atUhnvuaQeLncVgviR5z9k9ZzJbo7XOqvWgX7NS3nNRXiULXpQyfWA5f5MsmBRZWhVZfpO8DeEnY6yUQi6SPy_T4DwcTthP3lm0sNzWKzABEKw7Ug-tcQP6X-Q_wjcKUx8DuA7igcCj1W4wv0nDeMBAIGBb755BMAEhTvp0Ptw_bfZbwWDspwAW23RE1ZuIr9Svf9CgZtkaS7Dc15sVHAPUGzAWRk9H46bQn2Cy0RNG0h9goIghYjQKRrTqvJ6lnlTEHlCTdQq9MnZODMth_7le3SXXHfaB3v2bt8n3L08vj9t097z5-ljvUsUfijItuWyZqHhVyDJTZcXzohUCiSEjVeVcMFV1qOcWeZm3Mme6y1XR5ZXkSLrrstuEX_4q70Lw1DWjN3Nvp4az5kyouRBqLoSamdDs-XTx0BzsaMg3QRmyirTxpGKjnfmP-y8EMJ06</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Hendifar, A.</creator><creator>Bullock, A.</creator><creator>Seery, T.</creator><creator>Zheng, L.</creator><creator>Sigal, D.</creator><creator>Ritch, P.S.</creator><creator>Braiteh, F.S.</creator><creator>Zalupski, M.</creator><creator>Bahary, N.</creator><creator>Harris, W.</creator><creator>Pu, J.</creator><creator>Lian, F.</creator><creator>Zhu, J.</creator><creator>Wu, W.</creator><creator>Chondros, D.</creator><creator>Jiang, P.</creator><creator>Hingorani, S.R.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)</title><author>Hendifar, A. ; Bullock, A. ; Seery, T. ; Zheng, L. ; Sigal, D. ; Ritch, P.S. ; Braiteh, F.S. ; Zalupski, M. ; Bahary, N. ; Harris, W. ; Pu, J. ; Lian, F. ; Zhu, J. ; Wu, W. ; Chondros, D. ; Jiang, P. ; Hingorani, S.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1856-619b027175963c67145b22ae0a0ec74120c7fad092164b940df4c5f4791aedff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hendifar, A.</creatorcontrib><creatorcontrib>Bullock, A.</creatorcontrib><creatorcontrib>Seery, T.</creatorcontrib><creatorcontrib>Zheng, L.</creatorcontrib><creatorcontrib>Sigal, D.</creatorcontrib><creatorcontrib>Ritch, P.S.</creatorcontrib><creatorcontrib>Braiteh, F.S.</creatorcontrib><creatorcontrib>Zalupski, M.</creatorcontrib><creatorcontrib>Bahary, N.</creatorcontrib><creatorcontrib>Harris, W.</creatorcontrib><creatorcontrib>Pu, J.</creatorcontrib><creatorcontrib>Lian, F.</creatorcontrib><creatorcontrib>Zhu, J.</creatorcontrib><creatorcontrib>Wu, W.</creatorcontrib><creatorcontrib>Chondros, D.</creatorcontrib><creatorcontrib>Jiang, P.</creatorcontrib><creatorcontrib>Hingorani, S.R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hendifar, A.</au><au>Bullock, A.</au><au>Seery, T.</au><au>Zheng, L.</au><au>Sigal, D.</au><au>Ritch, P.S.</au><au>Braiteh, F.S.</au><au>Zalupski, M.</au><au>Bahary, N.</au><au>Harris, W.</au><au>Pu, J.</au><au>Lian, F.</au><au>Zhu, J.</au><au>Wu, W.</au><au>Chondros, D.</au><au>Jiang, P.</au><au>Hingorani, S.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v253</spage><epage>v254</epage><pages>v253-v254</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx369.126</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v253-v254 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx369_126 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T07%3A57%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20hyaluronan%20(HA)%20is%20a%20novel%20biomarker:%20Results%20of%20the%20randomized%20phase%202%20HALO%20202%20study%20of%20PEGPH20%20plus%20nab-paclitaxel/gemcitabine%20(PAG)%20vs%20AG%20in%20previously%20untreated,%20metastatic%20pancreatic%20ductal%20adenocarcinoma%20(mPDA)&rft.jtitle=Annals%20of%20oncology&rft.au=Hendifar,%20A.&rft.date=2017-09&rft.volume=28&rft.spage=v253&rft.epage=v254&rft.pages=v253-v254&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx369.126&rft_dat=%3Celsevier_cross%3ES0923753420380157%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420380157&rfr_iscdi=true |